Addressing Nonlinearity in the Exposure‐Response Relationship for a Genotoxic Carcinogen: Cancer Potency Estimates for Ethylene Oxide

Risk Analysis - Tập 24 Số 5 - Trang 1165-1183 - 2004
Christopher R. Kirman1, Lisa Sweeney, M. Jane Teta, Robert L. Sielken, Ciriaco Valdez‐Flores, R.J. Albertini, Michael L. Gargas
1The Sapphire Group, Inc., Cleveland, OH 44122, USA. [email protected]

Tóm tắt

Ethylene oxide (EO) has been identified as a carcinogen in laboratory animals. Although the precise mechanism of action is not known, tumors in animals exposed to EO are presumed to result from its genotoxicity. The overall weight of evidence for carcinogenicity from a large body of epidemiological data in the published literature remains limited. There is some evidence for an association between EO exposure and lympho/hematopoietic cancer mortality. Of these cancers, the evidence provided by two large cohorts with the longest follow‐up is most consistent for leukemia. Together with what is known about human leukemia and EO at the molecular level, there is a body of evidence that supports a plausible mode of action for EO as a potential leukemogen. Based on a consideration of the mode of action, the events leading from EO exposure to the development of leukemia (and therefore risk) are expected to be proportional to the square of the dose. In support of this hypothesis, a quadratic dose‐response model provided the best overall fit to the epidemiology data in the range of observation. Cancer dose‐response assessments based on human and animal data are presented using three different assumptions for extrapolating to low doses: (1) risk is linearly proportionate to dose; (2) there is no appreciable risk at low doses (margin‐of‐exposure or reference dose approach); and (3) risk below the point of departure continues to be proportionate to the square of the dose. The weight of evidence for EO supports the use of a nonlinear assessment. Therefore, exposures to concentrations below 37 μg/m3 are not likely to pose an appreciable risk of leukemia in human populations. However, if quantitative estimates of risk at low doses are desired and the mode of action for EO is considered, these risks are best quantified using the quadratic estimates of cancer potency, which are approximately 3.2‐ to 32‐fold lower, using alternative points of departure, than the linear estimates of cancer potency for EO. An approach is described for linking the selection of an appropriate point of departure to the confidence in the proposed mode of action. Despite high confidence in the proposed mode of action, a small linear component for the dose‐response relationship at low concentrations cannot be ruled out conclusively. Accordingly, a unit risk value of 4.5 × 10−8 (μg/m3)−1 was derived for EO, with a range of unit risk values of 1.4 × 10−8 to 1.4 × 10−7 (μg/m3)−1 reflecting the uncertainty associated with a theoretical linear term at low concentrations.

Từ khóa


Tài liệu tham khảo

Abrahams R. H., 1980, Safe Use of Ethylene Oxide

10.1006/rtph.1999.1305

CALEPA, 2002, Air Toxics Hot Spots Program Risk Assessment Guidelines. Part II

10.1006/taap.2000.8918

Embree J. W., 1975, Mutagenicity of ethylene oxide, Toxicology and Applied Pharmacology, 33, 172

10.1056/NEJM199907153410306

10.1006/taap.2001.9184

French J. E., 1983, Journal of Cell Biochemistry, 47

Furmanski P., 1987, The Mouse in Biomedical Research, 351

10.1002/em.2850160209

Greaves M., 2003, IARC Workshop on Mechanistic Considerations in the Design and Interpretation of Molecular Epidemiologic Studies of Cancer

Greife A. L., 1988, Development of a model for use in estimating exposure to ethylene oxide in a retrospective cohort mortality study, Scandinavian Journal of Work Environment and Health, 14, 29

Health Canada, 1999, Draft for Public Comments

Hogstedt C., 1979, A cohort study of mortality and cancer incidence in ethylene oxide production workers, British Journal of Industrial Medicne, 36, 276

10.1002/ajim.4700250607

10.1126/science.2999978

IRIS, 2002, Integrated Risk Information System, Online Database

Kantarjian H. M., 1987, Therapy‐related leukemia and myelodysplastic syndrome, Cancer, 40, 435

Karelova J., 1987, Results of cytogenetic testing of workers exposed to ethylene oxide, Journal of Hygiene, Epidemiology, Microbiology, and Immunology, 31, 119

10.1016/0165-7992(83)90071-4

10.1006/geno.1994.1603

10.1016/0165-7992(92)90033-E

Levine E. G., 1992, Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure, Seminars in Oncology, 19, 47

10.1016/0888-7543(89)90301-7

10.1126/science.278.5340.1059

10.1016/0041-008X(84)90030-9

10.1016/0041-008X(84)90031-0

10.1002/(SICI)1098-2280(1996)27:2<84::AID-EM2>3.3.CO;2-0

10.1016/S1383-5718(99)00129-1

Mrozek K., 1998, The Lyomphomas Canellos, 107

10.1182/blood.V83.6.1603.bloodjournal8361603

NTP Working Group, 1987, Toxicology and carcinogenesis studies of ethylene oxide in B6C3F1 mice inhalation studies, National Toxicology Program Technical Report Series, 326, 114

10.1182/blood.V86.6.2365.bloodjournal8662365

10.1182/blood.V86.9.3542.bloodjournal8693542

10.1016/0165-4608(91)90246-Q

Pedersen‐Bjergaard J., 1993, Therapy‐related myelodysplasia and acute myeloid leukemia, Cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen series, Leukemia, 7, 1975

10.1182/blood.V83.10.2780.2780

10.1016/0027-5107(81)90011-7

Pettenati M. LeBeau M. Lemons R. Shima E. Kawasaki E. Larson R. Sherr C. Diaz M. &Rowley J.(1987).Assignment of CSF‐1 to 5q33.1: Evidence for clustering of genes regulating hematopoiesis and for their involvement in the deletion of the long arm of chromosome 5 in myeloid disorders.Proceedings of the National Academy of Sciences of the USA 84 2970–2974.

Preston R. J.(1999a).Chromosomal Changes. IARC Scientific Publication No. 146.

10.1080/10408449991349212

Preston R. J.(2003). Personal communication.

10.1002/em.2850260303

10.1038/372143a0

10.1007/BF00295085

10.1007/BF01234675

10.1016/0165-1161(94)90035-3

10.1080/00039896.1985.10545884

10.1146/annurev.genet.32.1.495

10.1016/0165-1218(84)90043-0

Shore R. E., 1993, Ethylene oxide: An assessment of the epidemiological evidence on carcinogenicity, British Journal Industrial Medicine, 50, 971

10.1073/pnas.91.6.2250

10.1016/S1383-5718(97)00063-6

10.1016/0041-008X(84)90081-4

10.1093/oxfordjournals.aje.a116782

10.1056/NEJM199105163242004

Stefanski S. A., 1990, Pathology of the Fischer Rat

10.1016/0027-5107(84)90127-1

Stromberg P. C., 1985, Large granul lymphocyte leukemia in F344 rats: Model for human T lymphoma, malignant histiocytosis and T‐cell chromic lymphocytic leukemia, American Journal of Pathology, 119, 517

Swaen G. J. W., 1987, Pathology of Tumors in Laboratory Animals. Vol 1. Tumors of the Rats

10.1093/toxsci/71.1.27

10.1016/0027-5107(91)90205-3

Teta M. J., 1993, Mortality study of ethylene oxide workers in chemical manufacturing: A 10 year update, British Journal Industrial Medicine, 50, 704

10.1023/A:1007086728854

Thiess A. M., 1981, Mutagenicity study on workers exposed to alkene oxides (ethylene oxide/propylene oxide) and derivatives, Journal of Occupational Medicine, 23, 343

USEPA, 1985, Health Assessment Document for Ethylene Oxide

USEPA, 1997, Health Effects Assessment Summary Tables

USEPA. (1997b).Chemical And Radiation Leukemogenesis in Humans and Rodents and the Value of Rodent Models for Assessment Risks of Lymphohematopoietic Cancers. EPA/600/R‐97/090. 1997. Washington DC :United States Environmental Protection Agency.

USEPA. (1998).Integrated Risk Information System for Arsenic. DownloadedOctober 2002. Available at:http://www.epa.gov/iris/subst/0278.htm.

USEPA, 1999, Proposed Guidelines for Carcinogen Risk Assessment

USEPA, 2003, Draft Final Guidelines for Carcinogen Risk Assessment

10.1016/S0027-5107(99)00208-0

Van Sittert N. J., 1985, Cytogenetic, immunological, and haematological effects in workers in an ethylene oxide manufacturing plant, British Journal of Industrial Medicine, 42, 19

Walker V. E., 1992, Molecular dosimetry of ethylene oxide: formation and persistence of 7‐(2‐hydroxyethyl) guanine in DNA following repeated exposures of rats and mice, Cancer Research, 52, 4328

10.1093/carcin/21.9.1661

Ward J. M., 1990, Tumors of the Rat. Tumors of the Haematopoietic System, 125

10.1126/science.8438156

Yunis J. J., 1989, Mechanisms of ras mutation in myelodysplastic syndrome, Oncogene, 4, 609

Thông tin
Thông tin xuất bản

Risk Analysis

Tập 24 Số 5

1165-1183

Thông tin tác giả